Kornimate/medical-research-clean huggingface dataset:
study of lx4211 in subjects with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the safety, tolerability, and efficacy of lx4211 versus a placebo control in subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * males and females (non-childbearing potential), aged 18-65 years * diagnosis of type 2 diabetes mellitus for at least 6 months prior to screening * fasting plasma glucose ≤ 240 mg/dl prior to metformin washout * body mass index \< 42 kg/m\^2 * hba1c value of 7 to 11% * c-peptide ≥ 1.0 ng/ml * ability to provide written informed consent exclusion criteria: * history of type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, incontinence, or nocturia * use of any blood glucose lowering agent other than metformin * prior exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening * laboratory or electrocardiogram abnormalities deemed significant by the sponsor or the investigator * positive test result for glutamic acid decarboxylase (gad) antibody * surgery within 6 months of screening * exposure to any investigational agent or participation in any investigational trial within 30 days prior to day 1 * hypersensitivity to an sglt2 inhibitor * history of drug or alcohol abuse within the last 12 months
long-term training effects of rhythmic auditory stimulation on gait in patients with parkinson's disease

Conditions: Continuous Rhythmic Auditory Stimulation; Intermittent Rhythmic Auditory Stimulation

Summary: falls are common among patients with parkinson's disease (pd) and are the biggest contributors to loss of independent living, long-term institutionalization, and increased mortality. the purpose of this study was to explore whether an at-home based rhythmic auditory stimulation (ras) gait training program will decrease the number of falls in persons with pd with a history of falling. we also evaluated changes in clinical and kinematic parameters used to assess fall risk in this population. sixty participants diagnosed with idiopathic pd with at least 2 falls in the past 12 months, were randomly allocated into two groups. the experimental group trained daily with ras for 24 weeks. the control group also trained daily with ras, but discontinued training between weeks 8 and 16. during treatment patients walked for 30 minutes in a home based environment with metronome-click embedded music. changes in clinical and kinematic parameters were assessed at baseline, weeks 8, 16, and 24.


Eligibility criteria:
inclusion criteria: * hoehn \& yahr (hy) stage iii or iv * at least 2 falls in the past 12 months * stable antiparkinsonian medication regime * ability to ambulate independently for at least 50 m. exclusion criteria: * other neurological or orthopedic conditions * medically diagnosed hearing loss * dementia (mini mental status exam score \< 24).
effectiveness of prp, conditioned medium uc-mscs secretome and hyaluronic acid for the treatment of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the clinical trial will be carried out at the dr. moh. hoesin central hospital, palembang and planned from october 2022 to march 2023. this study aims to compare the efficacy of platelet rich plasma, conditioned medium from umbilical cord mesenchymal stem cell (msc) culture secretome and hyaluronic acid for the treatment of knee osteoarthritis

in this, prospective, open-label study, patients with mild to moderate symptomatic knee osteoarthritis will be randomized to receive either a series of platelet-rich plasma or hyaluronic acid or conditioned medium from umbilical cord mesenchymal stem cell (msc) culture secretome injections under ultrasound guidance. each of the groups were given 5 times injection 3 cc platelet-rich plasma or 2 cc hyaluronic acid or 2cc conditioned medium from umbilical cord msc secretome at intervals 1 weeks. clinical data in the form of subjective outcome measures will be collected pre-treatment and 6 months after injection.

Eligibility criteria:
inclusion criteria: * patients aged 30-60 years * suffering from grade 2 and 3 osteoarthritis (oa) was identified by two observers who differed accordingly the kellgren and lawrence research scale * patient with knee pain that had been continuing for at least 12 months with no relief using anti-inﬂammatory medications and that deteriorated with weight-bearing * patients can understand the nature of the study and written informed consent is given to patients exclusion criteria: * age \> 60 years * acute knee osteoarthritis effusions * patients are not willing to obey the study protocol * there are signs of infection local or general infection or positive serology for hiv, hepatitis and syphilis * there is a congenital disease that causes significant deformity of the knee can interfere with cell applications and interpret results * articular injection of the knee by any drug during the previous 3 months * participate in any clinical trial or treatment 30 days before the study * other conditions may, according to medical criteria, not support participation in this research (the recent history of knee trauma, autoimmune rheumatic diseases, uncontrolled systemic diseases such as diabetes or hypertension, patient with immunosuppressive or anticoagulant treatment and cancer)
methylene blue for the prevention of hypotension during hemodialysis

Conditions: Acute Kidney Injury; Shock

Summary: hypotension is a common complication of intermittent renal replacement therapy. methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. this trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.

this is a single-center, randomized, non-blind study, with a intention-to-treat analysis, aiming to evaluate whether the use of methylene blue reduces the incidence of hypotension during hemodialysis, resulting in a reduction in the need for therapeutic modifications during the session, defined as interruption session, reduced fluid losses and increased need for vasopressors. patients will be randomized using redcap platform in variable blocks of 4-6, stratified by center in a 1:1 ratio and by previous use of vasopressors, into two groups, intervention and usual treatment. access to randomization will be available 24 hours, 7 days a week. patients on intermittent renal replacement therapy will be selected to receive or not methylene blue at a bolus dose of 1 mg/kg, followed by a continuous infusion of 0.1 mg/kg of body weight in a total of 200 ml of solution. saline throughout the dialysis session. the usual care group will not receive any intervention.

Eligibility criteria:
inclusion criteria: 1. patient or legal representative accepted trial enrollment 2. age above 18 years 3. chronic or acute kidney injury in need for renal replacement therapy 4. blood pressure lower than 100 mmhg or in use of any vasopressor exclusion criteria: 1. pregnancy 2. death considered imminent in the next 24 hours 3. patients not on full code status 4. hypertensive patients where dialysis was indicated to remove fluids 5. known allergy to methylene blue 6. known glucose-6-phosphate deficiency 7. previously enrolled in the trial 8. acute coronary syndrome 9. domiciliary nitrate use
evaluation of apical root resorption in dental deep bite correction by twin slot orthodontic bracket

Conditions: Volumetric Root Resorption

Summary: evaluate the possible apical root resorption during deep bite correction by double slot bracket with low level slot versus high level slot using cbct.

group (a): patients will be treated with double slot brackets using low level slot in deep bite correction. group (b): patients will be treated with double slot brackets using high level slot in deep bite correction.

Eligibility criteria:
inclusion criteria: 1. female patients to avoid any sexual dimorphism which may affect the comparison. 2. age range from 18 to 23year. 3. patients with anterior dento alveolar deep bite. 4. angle class i or class ii malocclusion with minimal crowding. 5. healthy compliant and motivated patient. 6. no missing of any tooth except wisdom teeth exclusion criteria: * 1. previous orthodontic treatments. 2. any systemic or bone diseases. 3. pregnant and lactating patient. 4. prosthetic replacement in lower anterior teeth. 5. periodontitis with pocket depth more than 5 mm

Keywords: intrusion,root resorption
pet/ct and sentinel node in oral cancer

Conditions: Oral Cancer

Summary: in this study, the investigators want to pre-operatively scan patients who do not have any clinically suspicion of metastases with an 18f-fdg-pet/ct whole body scan , where after they go to lymphoscintigraphy incl. spect/ct and sentinel node biopsy. material from the oral cancer and, after permission of each patient, also normal oral tissue will be analyzed molecular-biologically. also a blood sample will be analyzed for molecular tumor markers. the investigators want to see if pet/ct is able to detect any signs of sub-clinically metastases. besides, the investigators want to fusion pet/ct with spect/ct data from the lymphoscintigraphy study and improve our pet/ct scanning with a dual-time pet scan of the head-and-neck region.

these patients are normally preoperatively sent to a ct scan of the thorax and abdomen; in this study, this ct is replaced by a wholebody pet/ct scan. afterwards, the patients goes to sentinel node lymphoscintigraphy and then to operation. by combining biomarkers and molecular imaging in patients with a clinically t1/t2n0m0 oral cancer, we want to characterize the tumor physiologically and correlate these physiological features to the clinical appearance of the cancer. aims of the study: * can pet/ct in this patient group metastases with consequently change of treatment? * can fusion of spect/ct and pet/ct with calculation of standardized uptake value (suv) indicate, how much tumor tissue there should be in a positive sentinel node to be detected by pet? * can dual-time pet scanning better determine lymph node metastases, than single-time pet scanning? * correlation between suv in pet with molecular-biological findings both in the primary tumor and in metastases

Eligibility criteria:
inclusion criteria: * biopsy-verified oral cancer * over 18 years of age exclusion criteria: * under 18 years of age * inable patients * pregnancy * known allergy to contrast agents * kidney insufficiency * other known cancer * diabetes mellitus * acute medical conditions such as acute infection, acute cardial or lung disease or other intercurrent diseases

Keywords: dual-time pet/ct sentinel node
viral triggers in pediatric lung transplantation

Conditions: Lung Transplant; Bronchiolitis Obliterans; Obliterative Bronchiolitis

Summary: the purpose of this study is to determine whether respiratory viral infections increase the risk of bronchiolitis obliterans syndrome (bos), obliterative bronchiolitis (ob), death, or retransplantation in children who have received lung transplants.


Eligibility criteria:
inclusion criteria: * parent or legal guardian willing and able to provide informed consent * participant of first single or bilateral heart-lung transplant exclusion criteria: * recipient of multi-organ transplant (aside from heart-lung) * condition or characteristic which in the opinion of the investigator makes the participant unlikely to complete the study

Keywords: lung transplant bos ob respiratory viral infection (rvi) lung disease
etiologies, investigations and outcomes of patients presenting with hemoptysis

Conditions: Hemoptysis; Haemoptysis; Lung Disease; Pneumonia; Tuberculosis; Bronchiectasis; Respiratory Tract Infections; Respiratory Tract Diseases; Bronchitis; Mycobacterium Infections; Bronchial Disease; Pulmonary Hemorrhage; Signs and Symptoms; Signs and Symptoms, Respiratory; Pathologic Processes; Mycosis; Hemorrhage; Lung Cancer; Pulmonary Embolism; Arteriovenous Fistula

Summary: the study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a north-american tertiary center.

rationale: hemoptysis, mild or massive, is worrisome for both patients and physicians. the management is different depending on the causes, which are not well defined for the north american population. despite the fact that this symptom is commonly reported in clinic, there are only a few studies published on this subject in the north-american population. tuberculosis was a frequent cause of hemoptysis described in populations overseas, which seems less prevalent in the investigators center. also, there are no known official guidelines regarding the investigation and management of hemoptysis. the investigators hypothesized that the use of modern technology in a north american population may result in different findings and provide a more accurate diagnostic approach. therefore, the study compares the different etiologies of hemoptysis and investigation modalities used in patients presenting in a north-american tertiary center. method: the investigators did a retrospective analysis of medical chart from patients with hemoptysis who visited the investigators center between 2005 and 2010. each visit has been reviewed individually to describe the characteristics of patients, etiologies of hemoptysis and investigation modalities used. all-cause mortality at 2 years was also recorded. descriptive statistical analyses will conducted on the data available.

Eligibility criteria:
inclusion criteria: any patient over the age of 18 presenting with: * a diagnosis of hemoptysis on an outpatient basis. * a diagnosis of hemoptysis during consultation in the emergency department. * a diagnosis of hemoptysis on the admission sheet. * a diagnosis of hemoptysis when hospitalized. * a complication of hemoptysis * hemoptysis on the report of the bronchoscopy, chest computed tomography, pulmonary angiography, ventilation-perfusion single-photon emission computed tomography or blood transfusion. exclusion criteria: * patients under 18 years of age. * patient who refused investigation for hemoptysis. * incomplete medical chart

Keywords: haemoptysis hemoptysis airway bleeding pulmonary hemorrhage
singstrong: strong lungs through song - long covid-19 study

Conditions: Long Covid

Summary: evidence is emerging that many individuals who recover from covid-19 are experiencing a range of residual problems. these include fatigue, pain, reduced exercise tolerance and breathing issues. this study includes participants who are experiencing problems with their lungs such as breathing difficulties, shortness of breath, and/or reduced exercise tolerance. the intervention is a twice weekly singing and breathing retraining intervention conducted over ten weeks. a range of self-report questionnaire measures will evaluate the efficacy of the intervention in addressing these problems. focus groups and individual interviews will also be used to gather information on the impact and acceptability of the programme.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * previous clinical diagnosis of covid-19 * ongoing issues with any or all of: shortness of breath, disordered breathing, reduced exercise tolerance * good written and spoken english language exclusion criteria: * lack of a confirmed covid-19 diagnosis * currently undergoing a similar singing or breathing retraining intervention * no residual problems from a confirmed case of covid-19

Keywords: singing disordered breathing covid-19
efficiency study of traditional chinese medicine (tcm) versus western medicine (wm) on ischemic stroke

Conditions: Stroke

Summary: complex project of traditional chinese medicine (tcm) with western medicine (wm) project under stroke unit mode contrast,assuming that the efficiency of tcm on early rehabilitation and secondary prevention of ischemic stroke is same or better than that of wm.

as a multi-site randomized controlled clinical trial,through a central system,patients were randomly assigned to the intervention group or the control group.in the intervention group, patients were treated with the traditional chinese medicine comprehensive rehabilitation program, which includes traditional chinese medicine syndrome differentiation herbs, chinese medicine injection, wash foam chinese medicine, acupuncture,massage, and chinese medicine health education. in the control group, patients were treated with western-based treatment plus modern rehabilitation techniques.all patients were treated for 2 weeks. at the first day after the treatment and the 14 days after treatment, each patient was evaluated for the following three clinical indications: (1)evaluation of neurological deficits by u.s. national institutes of health stroke scale (nihss);(2) evaluation of motor function by the short form fugl-meyer motor function scoring system (fmi); and (3) assessment of limb spasticity by the modified ashworth spasticity rating scale.

Eligibility criteria:
inclusion criteria: * according with the stroke diagnosis of traditional chinese medicine * according to atherosclerotic thrombotic cerebral infarction from western diagnosis such as medical history and ct / mri examinations * it has attacked in 7 days * the assessment of scale of nihss:4-24 points * age: ≥ 35 years and ≤ 75 years * patients or their legal guardians sign informed consent form exclusion criteria: * the patients with ich or cerebral hemorrhage or tia * it has attacked beyond 7 days * patients with stroke history and the mrs ≥ 2 points before this attack * mixed type of stroke (infarction after bleeding or bleeding after infarction) * patients with cerebral infarction by cardiogenic embolism, blood hypercoagulable state and tunica intima exfoliating * patients with serious heart disease;failure of heart or liver or kidney; cancer;digestive tract bleeding * women of pregnancy or breast-feeding * patients who are taking part in other clinical trials that will influence the results of this study

Keywords: stroke traditional chinese medicine rehabilitation
balugrastim (neugranin) in breast cancer participants receiving doxorubicin/docetaxel

Conditions: Chemotherapy-induced Neutropenia

Summary: determination of the effect of balugrastim on the duration and severity of severe neutropenia.


Eligibility criteria:
inclusion criteria: * breast cancer participants scheduled to receive the at regimen (doxorubicin/ docetaxel). exclusion criteria: * participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months).

Keywords: breast cancer supportive care neutropenia
erector spinae plane block vs. pecs i-ii blocks after breast-conserving surgery

Conditions: Breast Cancer Surgery; Breast Conserving Surgery; Erector Spinae Plane Block; Pectoral Nerve (PECS) Block; Visual Analog Scale; Opioid Consumption; Postoperative Pain, Acute

Summary: the goal of this study is to compare the analgesic effects of espb and pecs ii blocks in patients undergoing bcs. the main question it aims to answer is: * whether these two different block procedures will create a difference in postoperative pain scores. * comparison of total opioid consumption during the 24-hour postoperative period. our study included patients who were female, who were going to undergo elective breast-conserving surgery between march 2022 and august 2022.

the patients to be included in our study were divided into two groups as espb group or pecs ii group by an anesthesia assistant independent of the study using a computer-based randomization program one day before the operation. all patients were informed about the block in the preoperative period, the use of the patient-controlled analgesia device to be used after the operation, and visual analog scale (vas) assessment. (patients were asked to indicate their pain on a scale where 0 represented "no pain" and 10 represented "unbearable pain.) on the day of the operation, group envelopes were placed in the patient files to indicate the groups in sealed envelopes. the appropriate anesthesia method was applied to the patient according to the group written on the patient's envelope by the relevant anesthesiologist on duty in the study. our study was conducted as a randomized controlled and prospective study. vas scores at 0, 15, 30, 60 minutes postoperatively recorded for the primer output of the study. for the secondary outputs the total amount of analgesic used was recorded from the records of the pca device. all patients' demographic data, intraoperative hemodynamic data, anesthesia duration, surgical duration and hospital stay, vas at 4, 6, 12, 24 hours in the service follow-up, rescue analgesic requirements and numbers, nausea-vomiting and developing complications were evaluated and recorded. the evaluations were made by the anesthesiologist who was blind to the groups.

Eligibility criteria:
inclusion criteria: * female * age between 18-70 * underwent breast conserving surgery exclusion criteria: * patients with coagulopathy * known local anesthetic allergy * abnormal liver function tests * infection at the planned injection site * chronic usage of analgesics * under the age of 18 * over the age of 70 * asa (american society of anesthesiologists) iv and higher risk classes * limited cooperation for visual analog scale (vas) follow-ups

Keywords: erector spinae plane block pectoral nerve (pecs) block postoperative pain breast conserving surgery
evaluation of the efficacy of cesamet™ for the treatment of pain in patients with chemotherapy-induced neuropathy

Conditions: Peripheral Neuropathy; Antineoplastic Combined Chemotherapy Protocols

Summary: this study was designed to evaluate the safety and efficacy of cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.

to determine the safety and efficacy of cesamet™ in the symptomatic treatment of chemotherapy-induced neuropathic pain. this is a phase iv, multicenter, open label of cesamet™ at 1 mg daily progressing to 2mg bid in subjects with chemotherapy-induced neuropathic pain. this study has two phases: a pretreatment phase and a treatment phase.

Eligibility criteria:
inclusion criteria: * patients diagnosed with chemotherapy-induced neuropathic pain. * chronic daily pain present for at least 2 months. * on stable analgesic regimen for one month. * baseline pain score greater than 40mm on a vas. exclusion criteria: * hypersensitivity to compounds in study drug or similar drugs * pregnant or lactating females * drug or alcohol abuse * unstable medical condition

Keywords: chemotherapy-induced neuropathy cancer
the effect of bifidobacterium lactis and inulin on functional constipation

Conditions: Functional Constipation

Summary: the aim of this study is to asses the effect of bifidobacterium lactis and inulin on functional constipation in children


Eligibility criteria:
inclusion criteria: * children with functional constipation over 3 years age * below 18 years of age exclusion criteria: * chronic gastrointestinal disease, * hirschsprung disease, * celiac disease, * hypothyroids, * neurological deficit, * constipation treatment receiving children will be excluded